菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button ps_marketing@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button
CRO Services

Drug Development Expertise Empowering Research Services for Biologics

Bispecifics Discovery & Development Applications


Accelerate Your Bispecifics Projects with WuXi Biologics CRO Services

Looking to develop innovative bispecific or multi-specific antibodies? Our comprehensive service platform is designed to streamline every step, from early discovery to high-quality production and functional validation. Whether you’re advancing candidates for cancer immunotherapy or other therapeutic areas, we enable efficient, end-to-end development with speed, scale, and quality.

 

 

Our Bispecifics-Related Services:

  • Antibody Discovery: Provide a full suite of advanced platforms, including hybridoma, phage display, and single B screening, to rapidly identify and generate high-affinity bispecifics candidates.
  • Screening & Optimization: Improve developability and manufacturability through cutting-edge antibody design and engineering strategies.
  • Production: Overcome structural complexity with for diverse formats from high-throughput production to gram-level yields, delivering high-purity bispecifics for both in vitro and in vivo use.
  • In Vitro & In Vivo Characterization: Offer comprehensive functional assays and preclinical models to evaluate potency, mechanism of action, safety, and pharmacokinetics.

Antibody Design & Engineering

We provide tailored design and engineering solutions across diverse bispecifics formats, optimized for your specific therapeutic targets and mechanisms of action. 

Figure 1. BsAb optimization results demonstrated improved solubility, reduced non-specific binding, maintained binding affinity (Ka, Kd, KD), and preserved functionality .

 

High-Titer Production

Our expert team leverages innovative platforms for bispecific antibody engineering and production to deliver high-purity, gram-level bsAbs suitable for in vivo and in vitro studies.

Figure 2: Following multiple polishing steps, CrossMab achieved 98.4% heterodimer purity, as confirmed by Intact Mass analysis and SEC-HPLC.

 

Proven Expertise

With extensive expertise in bispecific antibody design, engineering, production, and analytics, our team has advanced over 100 bsAbs into CMC, with multiple projects successfully reaching IND filing.

 

Your Project. Our Expertise.